MET amplification/overexpression was identified either via (FISH; MET gene copy number (GCN) ≥ 5 or MET–CEP7 ratio ≥ 2) local tissue immunohistochemistry (MET +3 expression in ≥ 50% of tumor cells) or next-generation sequencing (≥20% tumor cells, coverage of ≥200 × sequencing depth and ≥5 copies of MET over tumor ploidy) [74]. This evidence concerns the gene MET and neoplasm.